Laurus Labs Invests $10M in Immune Therapy

Laurus Labs Invests $10M in Immune Therapy

Laurus Labs has acquired an additional 7.24% stake in ImmunoACT, a company involved in novel cell and gene therapy technologies for cancer treatment. It has also signed a memorandum of agreement with IIT Kanpur to fund the progression of some of the institute’s ground-breaking gene therapy assets through pre-clinical development, clinical trials, and market launch. Furthermore, it will establish a state-of-the-art Good Manufacturing Practice (GMP) facility at IIT Kanpur’s Techno Park to boost the production capabilities of gene therapy products.